"Amgen is applying the use of cutting-edge science and technology to attempt to target therapies to patients most likely to receive benefit," said Sean Harper. "We are committed to continue our work with the FDA to leverage our understanding of cancer biology in the Research & Development process, integrating biomarkers into ongoing clinical programs whenever scientifically feasible."
For more information on biomarkers and their potential role in the future of cancer treatment, prevention and detection, please visit http://www.amgen.com/media/virtual_press_kits.html.
About Colorectal Cancer
Colorectal cancer is the third most common cancer diagnosed in men and in women in the United States (U.S.). The American Cancer Society estimates that about 108,070 new cases of colon cancer and 40,740 new cases of rectal cancer will be diagnosed in 2008. Colorectal cancer is the second leading cause of cancer death among men and women in the U.S. and it has been estimated that more than 49,000 people will die from colorectal cancer in 2008. That means that one person in the U.S. dies of colorectal cancer every 9.3 minutes.
Vectibix is indicated for the treatment of patients with epidermal growth factor receptor- (EGFr) expressing metastatic colorectal cancer after disease progression on, or following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. The effectiveness of Vectibix for the treatment of EGFr-expressing, metastatic colorectal carcinoma is based on progression-free survival. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Vectibix.
Important Product Safety Information
Dermatologic Toxicity: Dermatologic toxicities occurred in 89
Copyright©2008 PR Newswire.
All rights reserved